The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 was determined by its ability to inhibit IGF-II induced proliferation of MCF-7. The expected ED50 for this effect is ≤ 0.2 µg/ml in presence of 15 ng/ml of human IGF-II.
% SDS-PAGE. Greater than 98% by SDS-PAGE and HPLC analyses.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Constituents: 20mM Sodium citrate, pH 4
Endotoxin level is less than 0.1 ng per µg (1EU/µg).
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionReconstitute with water to a concentration of 0.1-1.0mg/ml.
Acid stable subunit of the 140 K IGF complex
Binding protein 29
Binding protein 53
Growth hormone dependent binding protein
IGF binding protein 3
IGF-binding protein 3
Insulin Like Growth Factor Binding Protein 3
Insulin-like growth factor binding protein 3 precursor
Insulin-like growth factor-binding protein 3
FunctionIGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Tissue specificityExpressed by most tissues. Present in plasma.